Response to Stahlie et al regarding "A systematic review and meta-analysis of locoregional treatments for in-transit melanoma"

No Thumbnail Available
File version
Author(s)
Read, Tavis
Lonne, Michael
Sparks, David S
David, Michael
Wagels, Michael
Schaider, Helmut
Soyer, PeterH
Smithers, Mark B
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location
License
Abstract

To the Editor, We wish to thank Stahlie et al1 for their interest in our article. We did not include intralesional talimogene laherparepvec (T‐VEC) therapy in our analysis as we focused on locoregional treatments available in Australia and New Zealand. However, we commend them on highlighting the promising clinical results for T‐VEC. Since completing our systematic review, four studies have been published and these underscore the value of this treatment for patients with advanced disease.2-5 Additionally, the combination of T‐VEC with systemic immunotherapies including pembrolizumab will provide further evidence concerning their efficacy and safety profiles and preliminary results support this approach.6 Such combinations will also generate novel data that further define the survival outcomes of these patients.

Journal Title

Journal of Surgical Oncology

Conference Title
Book Title
Edition
Volume

120

Issue

6

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Science & Technology

Life Sciences & Biomedicine

Surgery

TALIMOGENE LAHERPAREPVEC

Persistent link to this record
Citation

Read, T; Lonne, M; Sparks, DS; David, M; Wagels, M; Schaider, H; Soyer, P; Smithers, MB, Response to Stahlie et al regarding "A systematic review and meta-analysis of locoregional treatments for in-transit melanoma", Journal of Surgical Oncology, 2019, 120 (6), pp. 1058-1059

Collections